Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC

This is a prospective, multi-centre randomised trial comparing between cTURBT plus 1-year BCG therapy, and ERBT plus 1-year BCG therapy, in patients with intermediate-risk or high-risk NMIBC.

Trial Details

NCT ID
NCT07724886
Phase
NA
Sponsor
Chinese University of Hong Kong
Status
RECRUITING
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Interventions
  • Conventional Transurethral Resection of Bladder Tumour
  • Transurethral En Bloc Resection of Bladder Tumour
Locations (sample)
  • Hong Kong, Hong Kong|22.27832,114.17469
  • Sheung Shui, Hong Kong|22.51667,114.11667

Key Eligibility Criteria

  • Age 18 years or above
  • Fulfil any one of the following three criteria:
  • Recurrent bladder tumour
  • Multiple bladder tumours

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →